- Home
- FIHL vs DNLI Comparison
FIHL vs DNLI Comparison
Compare FIHL & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- DNLI
- Stock Information
- Founded
- FIHL 2014
- DNLI 2013
- Country
- FIHL Bermuda
- DNLI United States
- Employees
- FIHL N/A
- DNLI N/A
- Industry
- FIHL
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FIHL
- DNLI Health Care
- Exchange
- FIHL Nasdaq
- DNLI Nasdaq
- Market Cap
- FIHL 1.8B
- DNLI 2.1B
- IPO Year
- FIHL 2023
- DNLI 2017
- Fundamental
- Price
- FIHL $18.09
- DNLI $15.42
- Analyst Decision
- FIHL Hold
- DNLI Strong Buy
- Analyst Count
- FIHL 7
- DNLI 15
- Target Price
- FIHL $20.43
- DNLI $33.50
- AVG Volume (30 Days)
- FIHL 506.0K
- DNLI 2.1M
- Earning Date
- FIHL 11-11-2025
- DNLI 11-05-2025
- Dividend Yield
- FIHL 3.31%
- DNLI N/A
- EPS Growth
- FIHL N/A
- DNLI N/A
- EPS
- FIHL N/A
- DNLI N/A
- Revenue
- FIHL $2,607,600,000.00
- DNLI N/A
- Revenue This Year
- FIHL $21.24
- DNLI N/A
- Revenue Next Year
- FIHL $5.01
- DNLI $95,463.19
- P/E Ratio
- FIHL N/A
- DNLI N/A
- Revenue Growth
- FIHL 21.21
- DNLI N/A
- 52 Week Low
- FIHL $14.17
- DNLI $10.57
- 52 Week High
- FIHL $21.32
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- FIHL 60.66
- DNLI 62.72
- Support Level
- FIHL $16.96
- DNLI $12.58
- Resistance Level
- FIHL $18.60
- DNLI $15.75
- Average True Range (ATR)
- FIHL 0.50
- DNLI 0.68
- MACD
- FIHL 0.03
- DNLI 0.24
- Stochastic Oscillator
- FIHL 69.09
- DNLI 89.59
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.